Placebo-controlled phase 3 study of oral BG-12 for relapsing MS

Data from this randomised, double-blind, placebo-controlled phase 3 study oral BG-12 in relapsing remitting MS (RRMS) shows a reduction in annualised relapse rate of approximately 50% compared to placebo.

Overall there was also a relative risk reduction for disability progression in treated patients of approximately a third. Using a three-times-a-day dosing regime was no superior to the twice-a-day dosing regimen.

Authors: Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators.

N Engl J Med. 2012 Sep 20;367(12):1098-107.

Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial